P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) - Dalovisio, A.; Bahlis, N.; Raje, N.; Costello, C.; Dholaria, B.; Solh, M.; Levy, M.; Tomasson, M.; Dube, H.; Damore, M.; Jiang, S.; Basu, C.; et al.